Table 1.
Clinical and Tumor Features in the Training and Validation Cohorts
| Characteristics | Training Cohort (N = 618) | Validation Cohort (N = 283) |
|---|---|---|
| Median age (years) | 53.28 | 49.86 |
| Race | ||
| White | 465 | 173 |
| Black | 108 | 93 |
| Others* | 36 | 8 |
| Not available | 9 | 9 |
| Menopausal status | ||
| Pre | 250 | 147 |
| Post | 356 | 132 |
| Not available | 12 | 4 |
| Tumor staging (size) | ||
| T1 | 302 | 95 |
| T2 | 246 | 145 |
| T3 | 59 | 31 |
| T4 | 8 | 12 |
| Not available | 3 | 0 |
| ER status | ||
| Positive | 536 | 137 |
| Negative | 82 | 146 |
| PR status | ||
| Positive | 486 | 103 |
| Negative | 132 | 180 |
| HER2 status | ||
| Positive | 89 | 66 |
| Negative | 529 | 217 |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor; *Includes Asian, Native, Hispanic.